Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12694758 | 0.90 | MTNR1A (0.39) | LMNASMN1; SMN2NPSR1MTNR1AIRAK4 | |
| SCHEMBL1062366 | 0.85 | PIM1 (0.39) | KDRP2RX3IRAK4PIM1 | |
| SCHEMBL4756377 | 0.85 | PIM1 (0.39) | KDRP2RX3IRAK4PIM1 | |
| SCHEMBL6913962 | 0.85 | PIM1 (0.39) | KDRP2RX3IRAK4PIM1 | |
| Hydrochloric Acid SCHEMBL629946 | 0.84 | PIM1 (0.39) | KDRP2RX3IRAK4PIM1 | |
| Hydrochloric Acid SCHEMBL3360571 | 0.84 | PIM1 (0.39) | KDRP2RX3IRAK4PIM1 | |
| SCHEMBL13433702 | 0.82 | PIM1 (0.39) | KDRP2RX3IRAK4PIM1 | |
| Hydrochloric Acid SCHEMBL3359714 | 0.81 | PIM1 (0.39) | KDRP2RX3IRAK4PIM1 | |
| SCHEMBL8229174 | 0.79 | IRAK4 (0.39) | IRAK4PIM1 | |
| SCHEMBL8185861 | 0.79 | GRIK1 (0.43) | LMNASMN1; SMN2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1913016-B1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8278322-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278322-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | LMNA 3730/4885SMN1; SMN2 4284/4885NPSR1 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.